UOC
SNDX icon

UBS O'Connor’s Syndax Pharmaceuticals SNDX Stock Holding History

UBS O'Connor’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-90,441
Closed -$847K – 432
2025
Q2 		$847K Buy
90,441
+31,003
+52% +$341K 0.02% 245
2025
Q1 		$730K Sell
59,438
-30,794
-34% -$434K 0.02% 208
2024
Q4 		$1.19M Buy
90,232
+751
+0.8% +$12.9K 0.03% 212
2024
Q3 		$1.72M Sell
89,481
-20,973
-19% -$433K 0.04% 196
2024
Q2 		$2.27M Buy
110,454
+2,023
+2% +$42.3K 0.06% 174
2024
Q1 		$2.58M Buy
108,431
+12,482
+13% +$278K 0.07% 140
2023
Q4 		$2.07M Buy
+95,949
New +$1.47M 0.07% 167

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

UBS O'Connor's SNDX Position: Q3 2025 in Review

UBS O'Connor sold out of Syndax Pharmaceuticals (SNDX) in Q3 2025, closing a stake of 90,441 shares — an estimated $847K sold.

UBS O'Connor first reported a position in SNDX in Q4 2023 and held it in 7 quarters. The position peaked at $2.58M in Q1 2024. 227 funds tracked by Wall St. Rank hold SNDX as of Q3 2025.

  • UBS O'Connor reported no remaining Syndax Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • UBS O'Connor sold 90,441 Syndax Pharmaceuticals shares in Q3 2025, an estimated $847K.
  • UBS O'Connor first reported a position in Syndax Pharmaceuticals in Q4 2023 and held it in 7 quarters.
  • UBS O'Connor's Syndax Pharmaceuticals position peaked at $2.58M in Q1 2024.
  • 227 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q3 2025.

Based on UBS O'Connor's 13F filing for Q3 2025, filed 14 Nov 2025.